Oryzon Genomics SA (ORY)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Mar 14, 2025

$3.11

P/E Ratio

N/A

Market Cap

$203.95M

Mar 27, 2024May 3, 2024Jun 5, 2024Jul 5, 2024Aug 7, 2024Sep 9, 2024Oct 11, 2024Nov 15, 2024Dec 20, 2024Jan 29, 2025Mar 14, 2025$0.00$10.00
  • PVA
Description
Add to research
View more

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.

Metrics
Add to research
View more

Overview

  • HQBarcelona, CT
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerORY
  • Price$3.114606+1.01%

Trading Information

  • Market cap$203.95M
  • Float82.95%
  • Average Daily Volume (1m)2,174,132
  • Average Daily Volume (3m)822,951
  • EPS-$0.06

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$3.67M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$4.33M
  • EV$98.58M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B2.33
  • Debt/Equity20.30
Documents
Add to research
View more